<- Go home

Professional

[BLOG] Idea Brunch

Added to YB: 2025-09-10

Pitch date: 2025-09-08

CPH.TO [bullish]

Cipher Pharmaceuticals Inc.

+14.07%

current return

Author Info

Idea Brunch is an interview series where great off-the-beaten-path investors share their best ideas and insights about their research process. Yellowbrick users get a 20% discount for life

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 16.77

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

value

Show full summary:
Idea Brunch with Anthony Fruci of Halvio Capital - Cipher Pharmaceuticals Inc.

CPH.TO: Specialty pharma w/ Epuris (50% severe acne market) + ParaPRO acquisition doubled EBITDA to ~$24M. Natroba has 23% scabies/lice share, superior to market leader Permethrin. Minimal debt, no capex means EBITDA=FCF. Targeting $50M EBITDA = 6x EV/FCF. CEO Craig Mull owns ~50%, proven allocator seeking more deals.

Read full article (1 min)